Overview

YF476 and Type II Gastric Carcinoids

Status:
Terminated

Trial end date:
2012-06-22

Target enrollment:

Participant gender:

Summary

This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Trio Medicines Ltd.

Collaborator:

National Institutes of Health (NIH)

Treatments:

Gastrins